Ari David Baron
0000-0003-1247-3094
Publication & Citation Trends
Publications
0 total
Bxq-350 in combination with FOLFOX7 and bevacizumab: Evaluation of effect on oxaliplatin-induced CIPN—A phase 1b/2 trial to assess the efficacy and safety of BXQ-350, a first-in-class sphingolipid metabolism modulator, in newly diagnosed metastatic colorectal carcinoma.
Cited by 0
Semantic Scholar
A phase 1b/2 study on the efficacy and safety of BXQ-350, a first-in-class sphingolipid metabolism modulator, in combination with mFOLFOX7 and bevacizumab in newly diagnosed metastatic colorectal carcinoma.
Cited by 0
Semantic Scholar
BXQ-350 efficacy and safety evaluation in first line mCRC patients: A phase 1b/2 study of BXQ-350, a first-in-class sphingolipid metabolism modulator, in combination with mFOLFOX7 plus bevacizumab in newly diagnosed metastatic colorectal carcinoma.
Cited by 0
Semantic Scholar
Complete remission in a patient with widely metastatic HER2-amplified pancreatic adenocarcinoma following multimodal therapy informed by tumor sequencing and organoid profiling OA
Cited by 1
Semantic Scholar
Research Topics
Hepatocellular Carcinoma Treatment and Prognosis
(52)
Colorectal Cancer Treatments and Studies
(19)
Cancer Immunotherapy and Biomarkers
(18)
Cancer Treatment and Pharmacology
(15)
Pancreatic and Hepatic Oncology Research
(14)
Affiliations
Sutter Health
University of Maryland, Baltimore
Merck & Co., Inc., Rahway, NJ, USA (United States)
Verizon (United States)
University of California, San Francisco